Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.

Article Details

Citation
Copy to clipboard

Kell J

Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.

Curr Opin Investig Drugs. 2007 Jun;8(6):485-92.

PubMed ID
17621879 [ View in PubMed
]
Abstract

MethylGene Inc, in collaboration with Pharmion Corp, is developing the small-molecule, isoform-selective compound MGCD-0103 in North America for the potential treatment of cancer. MGCD-0103 is currently undergoing phase II clinical trials in patients with lymphoma, leukemia, myelodysplastic syndromes and solid tumors, including pancreatic carcinoma. Taiho Pharmaceutical Co Ltd is evaluating MGCD-0103 for oncological indications in South East Asia.

DrugBank Data that Cites this Article

Drugs